Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
F Martins, L Sofiya, GP Sykiotis, F Lamine… - Nature reviews Clinical …, 2019 - nature.com
Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …
Drug-induced liver injury
RJ Andrade, N Chalasani, ES Björnsson… - Nature Reviews …, 2019 - nature.com
Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that
occurs either as a predictable event when an individual is exposed to toxic doses of some …
occurs either as a predictable event when an individual is exposed to toxic doses of some …
Immunotherapy in non–small cell lung cancer: facts and hopes
DB Doroshow, MF Sanmamed, K Hastings, K Politi… - Clinical Cancer …, 2019 - AACR
Abstract Immune-checkpoint inhibitors (ICI), particularly inhibitors of the PD-1 axis, have
altered the management of non–small cell lung cancer (NSCLC) over the last 10 years. First …
altered the management of non–small cell lung cancer (NSCLC) over the last 10 years. First …
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
EEW Cohen, RB Bell, CB Bifulco, B Burtness… - … for immunotherapy of …, 2019 - Springer
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …
sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and …
Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology
JA Thompson, BJ Schneider, J Brahmer… - Journal of the National …, 2019 - jnccn.org
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …
provide guidance on the management of immune-related adverse events resulting from …
Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer
A Simonaggio, JM Michot, AL Voisin, J Le Pavec… - JAMA …, 2019 - jamanetwork.com
Importance Although immune checkpoint inhibitors (ICIs), such as anti–PD-1 (programmed
cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in …
cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in …
Immune checkpoint inhibitor outcomes for patients with non–small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications
PURPOSE Baseline use of corticosteroids is associated with poor outcomes in patients with
non–small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition …
non–small-cell lung cancer (NSCLC) treated with programmed cell death-1 axis inhibition …
Adverse events following cancer immunotherapy: obstacles and opportunities
Oncology has recently undergone a revolutionary change with widespread adoption of
immunotherapy for many cancers. Immunotherapy using monoclonal antibodies against …
immunotherapy for many cancers. Immunotherapy using monoclonal antibodies against …
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
O Mamlouk, U Selamet, S Machado… - … for immunotherapy of …, 2019 - Springer
Abstract Rationale & Objective The approved therapeutic indication for immune checkpoint
inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the …
inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the …
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+ IPI: a systematic review …
P Xing, F Zhang, G Wang, Y Xu, C Li, S Wang… - … for immunotherapy of …, 2019 - Springer
Background Deciphering the correlation between immune-related adverse events (irAEs)
categorized by organ system class and clinical benefit of immunotherapy is critical for …
categorized by organ system class and clinical benefit of immunotherapy is critical for …